Navigation Links
GSK Does Not Option XL784 for Further Development
Date:1/18/2008

/p>

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential efficacy of Exelixis' compounds, including the other compounds on which GSK has an option, and the likelihood that GSK will exercise its option to license additional compounds for further development and commercialization. Words such as "believes," "intend," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the potential failure of Exelixis' compounds to demonstrate safety and efficacy in clinical testing and Exelixis' dependence on and relationship with GSK. These and other risk factors are discussed under "Risk Factors" and elsewhe
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
2. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
3. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
4. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
5. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
6. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
9. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. St. Jude Defines Eye Cancer Genes Role in Retinal Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners participated ... to Benefit the Radiation Oncology Institute (ROI), hosted by ... Golden Gate Park in San Francisco.  ... , CEO of Radiation Business Solutions, "but at ... raised over $70,000 for the ROI this year. This ...
(Date:9/19/2014)...  CytRx Corporation (Nasdaq: CYTR ), a ... announced that David J. Haen , Vice President, ... the Biotech Industry Conference on Friday, September 26 th ... place at the Millennium Broadway Hotel in ... and archived webcast of the presentation will be available ...
(Date:9/19/2014)... VIENNA, Austria , September 19, 2014 ... glucose control persist for many years in people with ... to produce major long term benefits for the kidneys." ... control in patients with type 2 diabetes leads to ... to usual care. The global study has ...
Breaking Medicine Technology:Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... Hope for Treatment of,Children, WHITE PLAINS, N.Y., Feb. ... rare craniofacial birth defect in,mice and holds promise to ... funded in part by the March of Dimes., ... Nature Medicine,demonstrates the potential for translating basic research into ...
... BEIJING, Feb. 6 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals,Inc. ... "Company"), a,pharmaceutical company in the People,s Republic ... achieved significant milestones in the development of,isosorbide ... drug,for the prevention and treatment of angina., ...
Cached Medicine Technology:Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 3
(Date:9/21/2014)... the physical activity benefits of active play, a new ... children, playing has no goal it is an ... alone or with friends, and it represents "an opportunity ... boredom, sadness, fear, or loneliness." "By focusing on the ... aspects of play that are beneficial to young people,s ...
(Date:9/21/2014)... BC (PRWEB) September 21, 2014 Burnaby ... educational information to clients in order to help them ... sessions held at the clinic that will help clients ... they can also take active participation in the healing ... and posture, clients will be able to facilitate the ...
(Date:9/21/2014)... 2014 Over the past five years, ... inundate the market, thereby cutting into revenue growth for ... to data from Industry Canada, the loss of patent ... and $2.5 billion in 2010 and 2012, respectively. “In ... which has hampered revenue growth, many pharmaceutical manufacturers have ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... BHWG) will host a statewide symposium ( tinyurl.com/ILBHC14 ... Veterans, and their Families. Sponsored by the VNA ... Lottery Cash Grant, and Health & Disability Advocates, ... at the Hilton Hotel in Springfield, IL. ...
(Date:9/21/2014)... SUNDAY, Sept. 21, 2014 (HealthDay News) -- Young women ... and know which foods they should eat. But they ... nutritional choices, according to a new study. ... the University of Illinois,s Peer Education Exercising and Eating ... what would they choose to eat if they were ...
Breaking Medicine News(10 mins):Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News: College Women Can Use Food Strategies, Study Finds 2
... Oct. 8 Boston Scientific,(NYSE: BSX ) announced ... third quarter results, which it plans to report on ... a $250 million milestone,payment from Abbott Laboratories (NYSE: ... Guidant,s vascular intervention and endovascular,solutions businesses. As a result, ...
... Weight Watchers,International, Inc. (NYSE: WTW ) ... serve as its President, North America, effective November,3, ... product,operations and general management experience, will oversee the ... products,publishing and licensing businesses and will be reporting ...
... sometimes goes awry has been implicated in breast cancer. ... of the Notch pathway may contribute to breast cancer. ... Drs Jane Visvader and Geoff Lindeman from the Victorian ... Notch genes in regulating breast development and function. ...
... Bulletin Board:,VYTC) today announced that effective October 7, ... an independent scientific consultant to Vyta Corp.,Dr. Sorgente ... at,BIOAGRA, LLC, a joint venture, equally owned by ... 2008, Vyta Corp announced its filing of,foreclosure litigation ...
... 8 Mass casualty incidents --,such as terrorist ... or hurricanes -- raise the life-and-death reality that,existing ... for all who,need it. One of the most ... requiring respiratory support., Disaster specialists and health ...
... Tampa, FL (Oct. 8, 2008) Women, the elderly, ... are all less likely to receive same-day coronary angioplasty ... South Florida researchers found. Their study was published this ... Cardiology . , Angioplasty, also known as percutaneous ...
Cached Medicine News:Health News:Boston Scientific Announces Third Quarter Adjustments 2Health News:Boston Scientific Announces Third Quarter Adjustments 3Health News:Boston Scientific Announces Third Quarter Adjustments 4Health News:Boston Scientific Announces Third Quarter Adjustments 5Health News:Weight Watchers Names Steven C. McCormick as President, North America 2Health News:Weight Watchers Names Steven C. McCormick as President, North America 3Health News:Vyta Corp Announces Engagement of Dr. Nino Sorgente as Independent Consultant 2Health News:Missouri Firm's New Ventilator Design Addresses Serious Homeland Security Issue 2Health News:Missouri Firm's New Ventilator Design Addresses Serious Homeland Security Issue 3Health News:Florida study finds barriers to angioplasty for life-threatening heart attacks 2Health News:Florida study finds barriers to angioplasty for life-threatening heart attacks 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: